162 related articles for article (PubMed ID: 28010166)
21. [Current status of the treatment of type 2 diabetes mellitus. Alpha-glucosidase inhibitors].
Blicklé JF; Andres E; Brogard JM
Rev Med Interne; 1999 Aug; 20 Suppl 3():379s-383s. PubMed ID: 10480189
[TBL] [Abstract][Full Text] [Related]
22. Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation.
Standl E; Schnell O
Diab Vasc Dis Res; 2012 Jul; 9(3):163-9. PubMed ID: 22508699
[TBL] [Abstract][Full Text] [Related]
23. Development and validation of HPLC-UV-MS method for the control of four anti-diabetic drugs in suspected counterfeit products.
Dai XM; An N; Wu JM; Li HY; Zhang QM
Yao Xue Xue Bao; 2010 Mar; 45(3):347-52. PubMed ID: 21348424
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.
Yamaguchi M; Saji T; Mita S; Kulmatycki K; He YL; Furihata K; Sekiguchi K
Int J Clin Pharmacol Ther; 2013 Aug; 51(8):641-51. PubMed ID: 23782587
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Cardiovascular Safety of Alpha Glucosidase Inhibitors.
Khwaja NUD; Arunagirinathan G
Curr Drug Saf; 2021; 16(2):122-128. PubMed ID: 33334296
[TBL] [Abstract][Full Text] [Related]
26. Comparison of adverse gastrointestinal effects of acarbose and miglitol in healthy men: a crossover study.
Aoki K; Muraoka T; Ito Y; Togashi Y; Terauchi Y
Intern Med; 2010; 49(12):1085-7. PubMed ID: 20558922
[TBL] [Abstract][Full Text] [Related]
27. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects.
Arakawa M; Ebato C; Mita T; Fujitani Y; Shimizu T; Watada H; Kawamori R; Hirose T
Metabolism; 2008 Sep; 57(9):1299-306. PubMed ID: 18702958
[TBL] [Abstract][Full Text] [Related]
28. Type 2 diabetes: glycemic targets and oral therapies for older patients.
Lardinois CK
Geriatrics; 1998 Nov; 53(11):22-3, 27-8, 33-4 passim. PubMed ID: 9824974
[TBL] [Abstract][Full Text] [Related]
29. Comparing the efficacy of α-glucosidase inhibitors in suppressing postprandial hyperglycemia using continuous glucose monitoring: a pilot study-the MAJOR study.
Tsujino D; Nishimura R; Taki K; Morimoto A; Tajima N; Utsunomiya K
Diabetes Technol Ther; 2011 Mar; 13(3):303-8. PubMed ID: 21291335
[TBL] [Abstract][Full Text] [Related]
30. Different effects of two alpha-glucosidase inhibitors, acarbose and voglibose, on serum 1,5-anhydroglucitol (1,5AG) level.
Watanabe K; Uchino H; Ohmura C; Tanaka Y; Onuma T; Kawamori R
J Diabetes Complications; 2004; 18(3):183-6. PubMed ID: 15145332
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the effects of acarbose and voglibose in healthy subjects.
Kageyama S; Nakamichi N; Sekino H; Nakano S
Clin Ther; 1997; 19(4):720-9. PubMed ID: 9377616
[TBL] [Abstract][Full Text] [Related]
32. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis.
van de Laar FA; Lucassen PL; Akkermans RP; van de Lisdonk EH; Rutten GE; van Weel C
Diabetes Care; 2005 Jan; 28(1):154-63. PubMed ID: 15616251
[TBL] [Abstract][Full Text] [Related]
33. Intestinal alpha-glucosidase inhibitors: abdominal gas cysts.
Prescrire Int; 2012 Sep; 21(130):212-3. PubMed ID: 23016254
[TBL] [Abstract][Full Text] [Related]
34. [Effects of voglibose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
Nakamura J
Nihon Rinsho; 2005 Feb; 63 Suppl 2():457-61. PubMed ID: 15779422
[No Abstract] [Full Text] [Related]
35. Synthetic α-glucosidase inhibitors as promising anti-diabetic agents: Recent developments and future challenges.
Mushtaq A; Azam U; Mehreen S; Naseer MM
Eur J Med Chem; 2023 Mar; 249():115119. PubMed ID: 36680985
[TBL] [Abstract][Full Text] [Related]
36. Interaction of antidiabetic α-glucosidase inhibitors and gut bacteria α-glucosidase.
Tan K; Tesar C; Wilton R; Jedrzejczak RP; Joachimiak A
Protein Sci; 2018 Aug; 27(8):1498-1508. PubMed ID: 29761590
[TBL] [Abstract][Full Text] [Related]
37. Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.
Kishimoto M; Noda M
Clin Drug Investig; 2015 Feb; 35(2):141-7. PubMed ID: 25511640
[TBL] [Abstract][Full Text] [Related]
38. [Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus].
Yamada K
Nihon Rinsho; 2003 Jul; 61(7):1219-23. PubMed ID: 12877088
[TBL] [Abstract][Full Text] [Related]
39. Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease.
Emoto T; Sawada T; Hashimoto M; Kageyama H; Terashita D; Mizoguchi T; Mizuguchi T; Motodi Y; Iwasaki M; Taira K; Okamoto H; Matsuo Y; Kim SK; Takarada A; Yokoyama M
Am J Cardiol; 2012 Jan; 109(1):42-6. PubMed ID: 21944671
[TBL] [Abstract][Full Text] [Related]
40. An Updated Overview of Synthetic α-glucosidase Inhibitors: Chemistry and Bioactivities.
Cai YS; Xie HX; Zhang JH; Li Y; Zhang J; Wang KM; Jiang CS
Curr Top Med Chem; 2023; 23(26):2488-2526. PubMed ID: 37818579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
